Galera Therapeutics posts FY 2025 net income of USD 149.05 million as R&D expense falls 88.93% to USD 0.35 million

Reuters03-19 19:16
Galera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts FY 2025 net income of USD 149.05 million as R&D expense falls 88.93% to USD 0.35 million
  • Galera published an annual report (Form 10-K) reporting net income of USD 149.05 million and a loss from operations of USD 2.54 million.
  • The company recorded a USD 151.05 million gain on extinguishment of debt after assigning its Blackstone royalty agreement obligations to Biossil, and also reported a USD 3.5 million gain on sale of dismutase mimetics assets tied to that transaction.
  • Research and development expense fell 88.92% to USD 0.35 million, driven mainly by lower personnel-related and share-based compensation following R&D staff terminations and wind-down of the GRECO trials.
  • General and administrative expense decreased 48.26% to USD 5.69 million, reflecting reduced headcount and lower legal and professional fees, insurance, and facilities costs.
  • Cash and cash equivalents were USD 6.4 million, and management said this is expected to fund operating expenses and capital expenditure requirements for at least twelve months from the date of filing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001563577-26-000005), on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment